What is Indigo BioAutomation?
Founded in 2006 as Indigo Biosystems, Indigo BioAutomation is a provider of automated data analysis, management, and integration solutions tailored for clinical laboratories, pharmaceutical research, and biotechnology operations. The company's core vision is to enhance laboratory operational efficiency through a data-centric approach, emphasizing direct access to raw data for informed decision-making. Indigo BioAutomation possesses deep expertise in mass spectrometry, laboratory process automation, big data analytics, and advanced algorithms, which are leveraged in its flagship product, ASCENT. This focus on high throughput laboratory environments aims to improve both efficiency and quality within scientific research and clinical settings.
How much funding has Indigo BioAutomation raised?
Indigo BioAutomation has raised a total of $10.7M across 3 funding rounds:
Private Equity
$1.8M
Series B
$8.5M
Debt
$350K
Private Equity (2010): $1.8M, investors not publicly disclosed
Series B (2014): $8.5M, investors not publicly disclosed
Debt (2020): $350K supported by PPP
Key Investors in Indigo BioAutomation
PPP
Public-Private Partnership
What's next for Indigo BioAutomation?
The recent major strategic investment, structured as debt financing, suggests Indigo BioAutomation is in a mature phase, potentially utilizing this capital for operational scaling, further product development, or strategic partnerships. The company's history of significant funding, including Private Equity and Series B rounds, indicates a trajectory of sustained growth and market penetration. Future advancements are likely to focus on refining its data-centric solutions to meet the evolving demands of high-throughput laboratories in the pharmaceutical and biotechnology industries, reinforcing its role as a key player in laboratory informatics.
See full Indigo BioAutomation company page
